Major Reform for Rare Disease Treatments on the Horizon in UK

Strategic Insights -

A new paper published by the Medicines and Healthcare products Regulatory Agency (MHRA) outlines a bold new approach to regulating rare disease therapies in the UK. The proposed reforms aim to speed up the development and approval of life-saving treatments for the estimated 3.5 million people living with a rare disease in the UK. The MHRA's plans include creating a new framework for rare disease therapies, which will prioritize patient-centered care and streamline the regulatory process. This move is part of the UK government's life sciences strategy and is supported by a newly formed Rare Disease Consortium, which brings together patients, advocacy groups, academia, and industry experts.

Key Takeaways:

  • The MHRA proposes a new framework for rare disease therapies that prioritizes patient-centered care and streamlines the regulatory process.
  • The framework aims to tackle the unique barriers that prevent life-changing rare disease therapies from reaching patients, including small patient numbers and difficult evidence generation.
  • The UK has the potential to become a global leader in rare disease innovation, driving inbound investment, transforming lives, and ensuring that no patient is left behind simply because their disease is rare.
  • The MHRA is working closely with patients, advocacy groups, academia, and industry experts through the newly formed Rare Disease Consortium to ensure that the reforms meet the needs of those affected by rare diseases.
  • The reforms aim to reduce the time it takes to develop and approve rare disease therapies from discovery to delivery, while maintaining strict standards of safety and efficacy.
  • The MHRA is committed to creating a single, unified approach to regulating rare disease therapies, rather than the current separate routes through regulatory approval.
  • The MHRA is also exploring the possibility of issuing early approvals for rare disease therapies based on compelling but limited evidence, with a strict safety monitoring plan in place.

Statistics:

  • 3.5 million people in the UK live with a rare disease, equivalent to one in 17.
  • Only 5% of rare diseases have an approved treatment.
  • The average diagnostic journey takes 5.6 years, and 30% of affected children die before the age of five.
  • The cost of delayed diagnosis and limited treatment options is estimated at £340 million annually.
  • The cost of inaction is estimated at £33 billion every year.

Sources:

  • M2 PressWIRE, November 3, 2025, "Major change for rare disease treatments on way, signals MHRA"
  • Medicines and Healthcare products Regulatory Agency (MHRA), new paper on regulatory framework for rare disease therapies